TY - JOUR
T1 - Immunomodulatory role of urolithin a on metabolic diseases
AU - Toney, Ashley Mulcahy
AU - Fox, Darius
AU - Chaidez, Virginia
AU - Ramer-Tait, Amanda E.
AU - Chung, Soonkyu
N1 - Funding Information:
This study was supported by a USDA-NIFA Grant awarded to S.C. and A.E.R.-T. (2017-67017-26781) and USDA predoctoral grant to A.M.T. (2019-67011-29518).
Funding Information:
Funding: This study was supported by a USDA-NIFA Grant awarded to S.C. and A.E.R.-T. (2017-67017-26781) and USDA predoctoral grant to A.M.T. (2019-67011-29518).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2
Y1 - 2021/2
N2 - Urolithin A (UroA) is a gut metabolite produced from ellagic acid-containing foods such as pomegranates, berries, and walnuts. UroA is of growing interest due to its therapeutic potential for various metabolic diseases based on immunomodulatory properties. Recent advances in UroA research suggest that UroA administration attenuates inflammation in various tissues, including the brain, adipose, heart, and liver tissues, leading to the potential delay or prevention of the onset of Alzheimer’s disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. In this review, we focus on recent updates of the anti-inflammatory function of UroA and summarize the potential mechanisms by which UroA may help attenuate the onset of diseases in a tissue-specific manner. Therefore, this review aims to shed new insights into UroA as a potent anti-inflammatory molecule to prevent immunometabolic diseases, either by dietary intervention with ellagic acid-rich food or by UroA administration as a new pharmaceutical drug.
AB - Urolithin A (UroA) is a gut metabolite produced from ellagic acid-containing foods such as pomegranates, berries, and walnuts. UroA is of growing interest due to its therapeutic potential for various metabolic diseases based on immunomodulatory properties. Recent advances in UroA research suggest that UroA administration attenuates inflammation in various tissues, including the brain, adipose, heart, and liver tissues, leading to the potential delay or prevention of the onset of Alzheimer’s disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. In this review, we focus on recent updates of the anti-inflammatory function of UroA and summarize the potential mechanisms by which UroA may help attenuate the onset of diseases in a tissue-specific manner. Therefore, this review aims to shed new insights into UroA as a potent anti-inflammatory molecule to prevent immunometabolic diseases, either by dietary intervention with ellagic acid-rich food or by UroA administration as a new pharmaceutical drug.
KW - Inflammation
KW - Insulin resistance
KW - Lipid metabolism
KW - Metabolic syndrome
KW - Mitochondria
KW - Nutri-tional sciences
KW - Obesity
KW - Urolithin A
UR - http://www.scopus.com/inward/record.url?scp=85101496150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101496150&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9020192
DO - 10.3390/biomedicines9020192
M3 - Review article
C2 - 33671880
AN - SCOPUS:85101496150
SN - 2227-9059
VL - 9
SP - 1
EP - 18
JO - Biomedicines
JF - Biomedicines
IS - 2
M1 - 192
ER -